naftazone has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azulay, JP; Benel, L; Boraud, T; Chaigneau, V; Cormier-Dequaire, F; Corvol, JC; Debilly, B; Dellapina, E; Durif, F; Eusebio, A; Galitzky, M; Guimarães-Costa, R; Haddad, R; Houot, M; Lacomblez, L; Mariani, LL; Meissner, WG; Rascol, O; Salis, A; Thalamas, C | 1 |
| Bossi, L; Brotchie, JM; Corvol, JC; Ferreira, J; Galitzky, M; Lacomblez, L; Lemarié, JC; Nègre-Pages, L; Perez-Lloret, S; Rascol, O | 1 |
2 trial(s) available for naftazone and Parkinson Disease
| Article | Year |
|---|---|
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naphthoquinones; Parkinson Disease; Treatment Outcome | 2019 |
A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesias; Female; Humans; Male; Naphthoquinones; Parkinson Disease; Pilot Projects; Placebos; Single-Blind Method; Treatment Outcome | 2012 |